Showing 7751-7760 of 8545 results for "".
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- CellCeuticals Nominated for Cosmetic Innovation Awardhttps://practicaldermatology.com/news/20120629-cellceuticals_nominated_for_cosmetic_innovation_award/2459777/CellCeuticals Skin Care, Inc., Biomedical Skin Treatments was named a finalist in two categories by the Independent Cosmetic Manufacturers and Distributors Association (ICMAD). InterActive Moisture Serum 2 was nominated for Best Skin Care P
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Stiefel, a GSK Company, Acquires Worldwide Rights to Toctino (alitretinoin)https://practicaldermatology.com/news/20120612-stiefel_a_gsk_company_acquires_worldwide_rights_to_toctino_alitretinoin/2459784/Stiefel, a GSK company, has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. A once-daily oral retinoid, Toctino is in Phase 3 trials in the US, where it has not yet received FDA approval. Globally, it is the only prescription medicine specifically
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- FotoFinder Unveils New Imaging Technologieshttps://practicaldermatology.com/news/20120604-fotofinder_unveils_new_imaging_technologies/2459790/FotoFinder presented new devices for early skin cancer detection at the World Congress of Dermoscopy in Brisbane last month. Among new developments is the connection of a mobile dermatoscope for iPhone with an online webspace where doctors can requ
- Study: FDA Approves Drugs Faster than Europe, Canadahttps://practicaldermatology.com/news/20120517-study_fda_approves_drugs_faster_than_europe_canada/2459797/Drugs are approved faster in the US than in Europe and Canada, new research from Yale University School of Medicine shows. Authors of the study, published in The New England Journal of Medicine, reviewed decisions from 2001 to 2010 by the FDA and regulators in Canada and Europe, Health Canada and th